John L Krstenansky

Prof. John L Krstenansky

orcid

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 1999 in Biochemistry
Verified
Journal Article
Closed access
SHStefan Hemmerich
Stefan Hemmerich
CPChad Paavola
Chad Paavola
ABAdam Bloom
Adam Bloom
SBSunil Bhakta
Sunil Bhakta
RFRichard Freedman
Richard Freedman
KJKurt Jarnagin
Kurt Jarnagin

18 October 1988 in Biochemistry
Verified
Journal Article
Closed access
SMSimon J. T. Mao
Simon J. T. Mao
MYMark T. Yates
Mark T. Yates
TOThomas J. Owen
Thomas J. Owen
JKJohn L Krstenansky
John L Krstenansky

19 January 1987 in FEBS Letters
Verified
Journal Article
Closed access
PDF file
JKJohn L Krstenansky
John L Krstenansky
SMSimon J.T. Mao
Simon J.T. Mao

1 November 1990 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
TSThue W. Schwartz
Thue W. Schwartz
JFJannie Fuhlendorff
Jannie Fuhlendorff
LKLise L. Kjems
Lise L. Kjems
MKMette S. Kristensen
Mette S. Kristensen
MVMees Vervelde
Mees Vervelde
BBBerith Bjørnholm
Berith Bjørnholm

1 August 1995 in Endocrinology
Verified
Journal Article
Closed access
DLD Leaffer
D Leaffer
MSM Sweeney
M Sweeney
LKL A Kellerman
L A Kellerman
ZAZ Avnur
Z Avnur
JKJohn L Krstenansky
John L Krstenansky
JCJ P Caulfield
J P Caulfield
RS-23581, a synthetic analog of human PTH-related protein-(1-34), and the amino-terminal 34 amino acids of bovine PTH [bPTH-(1-34)] increase bone mineral density. We wished to determine how quickly the ultrastructure of the osteogenic cells, i.e. osteoblasts and lining cells, of the cancellous bone of the second lumbar vertebra of ovariectomized rats was altered in response to the initiation and cessation of treatment. Ovariectomized rats were injected daily with 80 micrograms/kg RS-23581, bPTH-(1-34), or vehicle for 19 days. Animals were killed throughout the treatment period and during the ensuing 10 days. By 5 days after the initiation of treatment with either peptide, the cells on the trabecular surface were predominantly (> 90%) osteoblasts, with only a small increase in the total cell number. Throughout the dosing period, the relative area of the cytoplasm of osteogenic cells from rats treated with RS-23581 or bPTH-(1-34) was greater than that of cells from the ovariectomized control group, suggesting a relationship between bone formation and cytoplasmic mass. By 7 days after the cessation of treatment, the trabecular surface was covered predominantly by lining cells without a change in cell number. Thus, these peptides apparently promote the osteoblast phenotype; the osteoblasts revert to lining cells after the peptides are withdrawn.

1 January 1991 in Biochemistry
Verified
Journal Article
Closed access
LMLarry R. McLean
Larry R. McLean
KHKaren A. Hagaman
Karen A. Hagaman
TOThomas J. Owen
Thomas J. Owen
JKJohn L Krstenansky
John L Krstenansky